Interleukin-6 is an essential mediator of the bone loss caused by loss of estrogens. Because loss of androgens also causes bone loss, we have examined whether the IL-6 gene is regulated by androgens, and whether IL-6 plays a role in the bone loss caused by androgen deficiency. Both testosterone and dihydrotestosterone inhibited IL-6 production by murine bone marrow-derived stromal cells. In addition, testosterone, dihydrotestosterone, and adrenal androgens inhibited the expression of a chloramphenicol acetyl transferase reporter plasmid driven by the human IL-6 promoter in HeLa cells cotransfected with an androgen receptor expression plasmid; however, these steroids were ineffective when the cells were cotransfected with an estrogen receptor expression plasmid. In accordance with the in vitro findings, orchidectomy in mice caused an increase in the replication of osteoclast progenitors in the bone marrow which could be prevented by androgen replacement or administration of an IL-6 neutralizing antibody. Moreover, bone histomorphometric analysis of trabecular bone revealed that, in contrast to IL-6 sufficient mice which exhibited increased osteoclast numbers and bone loss following orchidectomy, IL-6 deficient mice (generated by targeted gene disruption) did not. This evidence demonstrates that male sex steroids, acting through the androgen-specific receptor, inhibit the expression of the IL-6 gene; and that IL-6 mediates the upregulation of osteoclastogenesis and therefore the bone loss caused by androgen deficiency, as it does in estrogen deficiency. (J.
Introduction
A series of recent observations by us and others have elucidated a link between estrogens, IL-6, and the bone loss associated with estrogen deficiency (1) . Thus, 17,6-estradiol inhibits the production of IL-6 by cells of the stromal/osteoblastic lineage from rodents and humans (2) . This effect is apparently mediated at the level of gene transcription, as evidenced by the fact that 176-estradiol inhibits the stimulated activity of the human IL-6 gene promoter by an estrogen receptor-dependent mechanism (3) . Upon loss of ovarian function, IL-6 production is increased in ex vivo cultures of marrow cells from ovariectomized mice, compared with cultures of marrow cells from shamoperated animals (4) . Similarly, IL-6 secretion is increased in human bone marrow after menopause or after discontinuation of estrogen replacement therapy (5) . Furthermore, loss of ovarian function in mice causes an upregulation of osteoclast precursor formation in the marrow as well as an increase in the number of osteoclasts in trabecular bone. These changes are apparently mediated by IL-6 as evidenced by the ability of an IL-6 neutralizing antibody to prevent them (6) . Consistent with this evidence, IL-6-deficient mice do not lose bone upon ovariectomy (7) .
Inherited or acquired disorders of testicular function are associated with bone loss. Indeed, congenital male hypogonadism is associated with osteoporosis (8-10); and bone mass in these individuals can be increased by administration of testosterone. Similarly, castration in men causes increased bone resorption and bone loss (11, 12) . In addition, low levels of testosterone correlate with decreased bone mineral density and increased risk of fracture in elderly men (13) (14) (15) . As in humans, orchidectomy in the rat causes bone loss that is characterized by increased endosteal bone resorption, as well as loss of trabecular bone and increased osteoclast numbers. These changes can be prevented by administration of either testosterone or dihydrotestosterone (16) .
Based on the evidence linking IL-6, osteoclastogenesis and bone homeostasis with estrogen loss (2) (3) (4) (5) (6) (7) , and the observation that testosterone also inhibits IL-6 production by bone marrow stromal cells (2) , we have hypothesized that the bone sparing effect of androgens is due to their ability to inhibit IL-6 production; and that IL-6 is the mediator of the bone loss that follows loss of testicular function. To test this hypothesis, we have performed in vitro studies to examine the mechanism of the regulation of the IL-6 gene by androgens and the role of the androgen receptor in this effect. In addition, we have investigated whether orchidectomy in mice causes an 11-6-mediated upregulation of osteoclastogenesis and bone loss in the male, as occurs upon ovariectomy in the female.
Methods
Chemicals and reagents. Recombinant human IIL-1,3, s.a. 1.8 x 107 U/ mg, was donated by the Biological Resources Branch of the Biological the media were removed and replaced with fresh media containing 2% FBS, and cultures were continued for another 24 h before performing the receptor binding studies. HeLa cells used for the transfection experiments were obtained from American Type Culture Collection (Rockville, MD) and maintained in DME supplemented with 5% FBS.
Quantification ofIL-6 secretion by +/+ LDA.JI cells. +/+ LDA. 11 cells were seeded in 2 cm2 wells at 105/well and cultured in 1.0 ml of phenol red-free McCoy's SA medium supplemented with 10% FBS, penicillin (100 U/ml), and streptomycin (100 ug/ml) at 37°C in 5% CO2. After 24 h, the medium was replaced with fresh medium containing 2% FBS without or with various concentrations of testosterone or dihydrotestosterone. 20 h later, recombinant human IL-1/ (500 U/ml) and recombinant human TNFa (50 U/ml) were added and the cultures maintained for an additional 24 h. Then, the media was collected and stored at -70°C. The cell layer was rinsed with PBS and cells were harvested by trypsinization and counted in a Coulter counter (Coulter Electronics, Hialeah, FL). IL-6 levels in culture supernatants were determined using the B9 cell bioassay as we have previously described (2 0 .1% gelatin buffer containing 0.1 M NaH2PO4, 0.15 M NaCI, and 0.015 M sodium azide), and subsequent centrifugation at 2,500 g for 20 min. Radioactivity was determined in supernatants using a liquid scintillation counter. Specific binding was determined by subtracting the mean cpm in the presence of unlabeled R1881 (or other unlabeled steroid) from the mean cpm of the corresponding tubes containing only 3H-R1881. The protein concentration of cytosol preparations was determined using a Bio-Rad protein assay kit (Hercules, CA). For Scatchard analysis, the best fit line was determined by linear regression and a 3 test influence diagnostic (Cook's distance, leverage coefficient, and DFHITS) was performed to detect outliers that could have a disproportionately strong influence on the calculation of the regression line (18) .
Construction ofthe reporter plasmid. The human IL-6 promoter was amplified by polymerase chain reaction using human genomic DNA as the template, and primers and conditions described elsewhere (3). The 1.2-kb long promoter was subsequently subcloned into the reporter plasmid pUCAT-l and its identity with the known sequence of the human IL-6 promoter was confirmed by restriction mapping and sequencing. For the work presented in this paper, a reporter plasmid containing the 225-pb proximal portion of the promoter (IL-6-CAT) was prepared by digesting the 1.2 kb IL-6 promoter-CAT plasmid with BamHI and NheI, filling in with Klenow fragment of DNA polymerase to create blunt ends, and religation.
Transfections. HeLa cells were cultured in DME containing 5% FBS in 10-cm tissue culture dishes. Cells were transfected when they reached 50-60% confluence. 3 h before transfection, cells were washed with PBS and phenol red-free DME medium without serum and containing 0.5% BSA was added. Transfections were performed using the calcium phosphate precipitation method followed by glycerol shock (19) . Cells were transfected with 10 jg of the reporter plasmid IL-6-CAT, 5 Animals. Male C57B1/6 or Swiss Webster mice, weighing 22-30 g and -60 d old, were obtained from Taconic Farms (Germantown, NY). IL-6-deficient mice were generated using standard homologous recombination techniques in which 95% of exon IV of the 11L-6 gene was replaced with the neomycin resistance gene and inserted in E14.1 embryonic stem cells (from strain 12901a) as previously described (21) . After establishing germline transmission, animals heterozygous for the 11L-6 mutation were intercrossed to yield mice that were homozygous for either the wild type 11L-6 gene (designated as " + / + " ) or the mutated IL-6 gene (designated as "-/-"). Subsequently, a colony of + / + mice and a colony of -/ -mice were maintained by random breeding of the respective homozygous + / + or -/ -mice. Three month old male progeny (four generations after establishing each colony) of either + / + or -/ -homozygous parents were used in these experiments. The 11L-6 genotype ( + / + or -/-) was confirmed by Southern blotting using DNA prepared from the distal portion of the tail (Qiagen, Chatsworth, CA). After digestion with BamIHl and electrophoresis, blots were probed with a 1.1-kb EcoRI fragment corresponding to exon V of the IL-6 gene. DNA from wild type mice exhibited a 6-kb band, whereas DNA from 11L-6 deficient mice exhibited a 3.7-kb band due to the presence of a BamHI restriction site in the DNA construct inserted into the 11L-6 locus (21) .
Male mice were sham-operated or orchidectomized. In the case of experiments using C57B 1/6 or Swiss-Webster mice, some animals were implanted subcutaneously, immediately after orchidectomy, with pellets containing testosterone (Innovative Research of America, Toledo, OH), which was released from the pellet over a 3-wk period. In the case of experiments lasting 4 wk between orchidectomy and sacrifice of the animals, testosterone pellets were again implanted at 3 wk after the operation. Approximately 24 h after the operation, some orchidectomized animals were injected (i.p.) with 1 mg of a neutralizing rat monoclonal antibody to murine 11L-6 (20F3) (22) provided by DNAX Research Institute for Cellular and Molecular Biology (Palo Alto, CA).
The 1L-6 neutralizing antibody was administered at 7-d intervals thereafter.
Animals were anesthetized and then killed by heart puncture, at either 4 wk (see Fig. 5 ), or two weeks (see Figs. 6 and 7) after the operation. Serum was collected for determination of total testosterone by radioimmunoassay (Diagnostics Products Corp., Los Angeles, CA) to confirm loss of androgens. The level of testosterone in serum of sham-operated mice was 30-600 ng/ml, whereas it was undetectable (< 10 ng/ml) in serum from orchidectomized mice. Tibiae were removed for histomorphometric analysis and femurs were removed for harvest of bone marrow cells. To isolate marrow cells, the ends of the bones were cut and the cells were obtained from the marrow by flushing with MEM (GIBCO BRL) containing 10% FCS (Sigma Chemical Co.), using a syringe fitted with 25-gauge needle. After the cells were rinsed, the nucleated cell count was determined using a Coulter Counter.
Bone histomorphometry. 
Results
The effect of testosterone and dihydrotestosterone, the nonaromatizable and bioactive metabolite of testosterone, on IL-6 production was compared in murine stromal cells. The + / +LDAL1 cells used as a model in these experiments exhibit characteristics of adventitial reticular cells of the marrow stroma, and secrete IL-6 upon stimulation with IL-1 and tumor necrosis factor (TNF) (2) . Pretreatment with either testosterone or dihydrotestosterone caused a dose dependent inhibition of IL-1 + TNF-stimulated IL-6 production by +/+LDAll cells (Table I ). The potency of the two steroids was similar.
To investigate whether the inhibitory effect of testosterone and dihydrotestosterone on IL-6 production was mediated by the classical androgen receptor, as opposed to the estrogen receptor that is expressed in these cells (25) , we performed binding studies of the androgen analog 3H-R1881 to cytosol preparations of + / + LDAl cells. Scatchard analysis of the binding of 3H-R1881 demonstrated the presence of 334±46 high affinity (Kd = 1.15±0.10 X 10-M) binding sites per cell (Fig. 1 A) .
This binding was specific for the tritiated ligand as evidenced by the ability of unlabeled R1881 to displace 3H-R1881 (Fig.  1 B) . Consistent with androgen receptor specificity, the binding of 3H-R1881 was not displaced by the progesterone analog R5020, or the synthetic glucocorticoids dexamethasone and triamcinolone, or the synthetic estrogen analog diethylstilbestrol. This binding profile is similar to that displayed by the androgen receptor in osteoblastic cells (26) (27) (28) .
The role of the androgen receptor in the regulation of 11L-6 production was firmly established in experiments whereby HeLa cells were transiently cotransfected with a plasmid containing the proximal 225-pb of the human IL-6 promoter driving the chloramphenicol acetyl transferase (CAT) reporter gene and an androgen receptor expression plasmid. As we have reported earlier (3), the activity of this promoter was stimulated by treatment of the cells with 160 nM phorbol 12-myristate 13-acetate (TPA) for 24 h (Fig. 2 A) . Pretreatment of the transfected cells with testosterone (10-8 M) or dihydrotestosterone (iO-g M or 10-6 M) completely inhibited the TPA-stimu- (Fig. 2 B) . On the other hand, dihydrotestosterone exhibited a consistent inhibiting effect on the activity of the IL-6 promoter. The potency of dihydrotestosterone and testosterone in inhibiting the activity of the 11L-6 promoter was similar in these transfection experiments, as it was in the inhibition of bioassayable IL-6 production by +/+LDAl1 cells. The dependency of the inhibiting effect of sex steroids on their respective receptors was determined by examining the effect of testosterone, dihydrotestosterone, and 17,B-estradiol, on CAT expression in HeLa cells cotransfected with the 1L-6-CAT promoter construct and an estrogen receptor expression plasmid instead of the androgen receptor plasmid. We found that, as opposed to the androgen receptor transfected cells, in HeLa cells transfected with the estrogen receptor plasmid and the IL-6-CAT construct, 17,6-estradiol exerted a potent inhibiting effect on the IL-6 promoter activity; whereas testosterone and dihydrotestosterone, even at concentrations as high as 10-6 M, were ineffective (Fig. 3) . Preincubation of the transfected cells with 17,6-estradiol, testosterone or dihydrotestosterone had no effect on TPA-stimulated activity of the IL-6 promoter when cells were cotransfected with a control plasmid (pBluescript) instead of the estrogen receptor or androgen receptor expression plasmid (data not shown). Adrenal androgens have high affinity for the androgen receptor (29) . We have therefore also examined whether androstenediol, androstenedione or dehydroepiandrosterone sulfate had an effect on the transcriptional activity of the IL-6 promoter. Pretreatment of HeLa cells cotransfected with the IL-6 reporter plasmid and the androgen receptor expression plasmid with adrenal androgens caused inhibition of the activity of the IL-6 promoter (Fig. 4) .
The relevance of the in vitro observations to the in vivo situation was assessed by performing orchidectomy in mice and examining its impact on the bone. Orchidectomy caused a decrease in the volume of trabecular bone in the secondary spongiosa of the proximal metaphysis of the tibia ( Fig. 5 A) ; as well as an increase in the number of osteoclasts (Fig. 5 B) . (Fig. 5 C) .
In a different experiment, ex vivo cultures of marrow cells were established from sham-operated or orchidectomized animals; and the number of CFU-GM, the presumed osteoclast progenitor, was determined. Orchidectomy had a relatively small effect on the absolute number of CFU-GM in the marrow (Fig. 6 ), but greatly increased CFU-GM replication, as assessed by determining the number of CFU-GM in S-phase. Administration of either testosterone (0.5 mg in slow release pellets) or weekly injections of 1 mg of an IL-6 neutralizing antibody, prevented the increase in CFU-GM numbers; and both of these agents completely suppressed CFU-GM cycling in orchidectomized mice to levels below that of sham-operated mice.
The role of 11L-6 in orchidectomy-induced bone loss and upregulation of osteoclast formation was also examined by comparing the effects of orchidectomy in 1L-6 sufficient and 11L-6 deficient mice generated by targeted gene disruption (21) . Unlike the experiments shown in Fig. 5 where we examined orchidectomized animals at 4 wk after the operation, in these studies, orchidectomized animals were studied at 2 wk after the operation. The reason for this change in the experimental protocol was to optimize our ability to detect changes in osteoclast numbers in bone sections. The amount of trabecular bone was not significantly different between sham-operated 1L-6 replete vs.
IL-6 deficient mice (Fig. 7 A) . Similarly, there was no difference in the number of osteoclasts per mm bone surface between sham-operated IL-6 sufficient and sham-operated IL-6 deficient mice (Fig. 7 B) . However, orchidectomy caused loss of trabecular bone in the secondary spongiosa of the tibia of the IL-6 replete mice, but it had no such effect in the IL-6 deficient mice (Fig. 7 A) . Furthermore, orchidectomy caused an increase in the number of osteoclasts identified in sections of tibia from the IL-6 sufficient mice. This change was absent in the bone of the orchidectomized 11L-6 deficient mice (Fig. 7 B) . Consistent with the histomorphometric data, osteoclast formation in bone marrow cultures from orchidectomized 11L-6 sufficient mice was increased when compared with sham-operated controls. In contrast, orchidectomy had no effect on osteoclast formation in bone marrow cell cultures from the 11L-6 deficient mice (Fig. 7  C) . In these experiments, we have utilized + / + and -/ -mice that are fourth generation descendants of the original intercross (Fl) 12901a X C57B1/6 founder animals. Therefore, there might be slight strain background variation between the two groups. Nonetheless, it is very unlikely that such small variation could account for their strikingly different bone response to orchidectomy.
Discussion
Because of the striking similarities between the adverse effects of estrogen loss and androgen loss on bone homeostasis, we have investigated here the possibility that similar molecular, biochemical and cellular mechanisms underlie the bone protective effects of both classes of sex steroids.
Our findings demonstrate that stromal cells of the marrow contain androgen receptors. This observation, together with the demonstration of receptors for estrogens in the same cells (25) , indicates that the marrow stroma has the necessary prerequisites IL-6, Bone Homeostasis and Androgens 2891 
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Sham ORX ORX+T ORX+alL46 Figure 6 . Effect of testosterone and IL-6 neutralizing antibody on CFU-GM in the bone marrow of orchidectomized mice. Swiss-Webster male mice were either sham-operated or orchidectomized. Orchidectomized animals were then left untreated (ORX) or were implanted with pellets containing 0.1 mg testosterone (ORX + T), or received weekly intraperitoneal injections of 1 mg of an IL-6 neutralizing antibody (ORX + aIL-6). 2 wk after surgery, animals were killed and bone marrow cells were obtained from the femur; the total number of CFU-GM and the number of cycling CFU-GM in the femur of each animal was determined as described in Methods. Open bars represent the mean (±SEM) number of CFU-GM per femur; closed bars represent the mean (±SEM) number of cycling CFU-GM per femur (n = 4 animals per group). Data were analyzed by one-way ANOVA * P < 0.05, vs. Sham, ORX + T, and ORX + aIL-6 total CFU-GM; * * * P < 0.01 versus Sham, ORX, + T, and ORX + aIL-6 cycling CFU-GM; * P < 0.01 versus Sham cycling CFU-GM as determined by the Student-Neuman-Keuls test. Similar data was obtained in a second experiment.
to respond to either class of sex steroids. Our estimate of the concentration of the androgen receptor in the bone marrowderived stromal cells is similar to the concentrations reported in osteoblastic cells (26) (27) (28) . In addition, the affinity for the analog R1881 and the binding specificity of the androgen receptor in the bone marrow stromal cells is practically identical to the affinity and specificity of the androgen receptor in prostate and osteoblastic cells (-10-10 M) (26) (27) (28) (29) . A portion of the binding of the labeled androgen analog could not be displaced by the unlabeled analog in our experiments. This may be due to the presence of residual low affinity androgen binding proteins such as sex steroid binding globulins from the serum, or other low affinity intracellular binding proteins (28).
We have previously reported that, like 17,3-estradiol, testosterone inhibits IL-6 production by murine bone marrow derived stromal cells (2) . However we did not know whether the inhibiting effect of testosterone on 11L-6 production was mediated by the estrogen receptor or the androgen receptor; or whether the effect of testosterone was mediated by estrogenic metabolites of testosterone that were produced upon in vitro aromatization (31, 32) . The demonstration of androgen receptors in stromal cells of the bone marrow, taken together with the finding that dihydrotestosterone can inhibit 11L-6 production as effectively as testosterone, suggests that testosterone regulates IL-6 production directly, rather than through the conversion of testosterone to estrogenic metabolites. The role of the androgen receptor in the androgen-induced inhibition of 11L-6 was firmly established in these studies by the demonstration that the androgen receptor expression plasmid is required for eliciting the inhibiting effect of testosterone on the activity of the IL-6 promoter. In fact, the results of the experiments where HeLa cells were cotransfected with either the androgen receptor or the estrogen receptor expression plasmid indicate that whereas both androgens and estrogens can inhibit IL-6, their effects are strictly dependent on the expression of their respective receptor, and cannot be due to actions of androgens mediated by the estrogen receptor or vice versa. In our earlier studies, we had determined that the effect of estradiol on the transcriptional activity of the human IL-6 promoter is not mediated by direct interaction of the human estrogen receptor with the IL-6 promoter, but perhaps through an interference with events along the signal pathways initiated by the IL-6 stimulating agents (3) . Identical conclusions were reached in studies reported by Ray et al. (33) . We have not examined here whether the androgen receptor interacts directly with the IL-6 promoter. Nonetheless, the 225-bp segment of the IL-6 promoter used in the transient transfection experiments does not contain consensus DNA binding sites for the androgen receptor, nor does it contain glucocorticoid response elements which can bind the androgen receptor (34) (35) (36) (37) . In view of this, and the results of our earlier studies with estrogens, it is likely that the androgen receptor acts to inhibit the activity of the IL-6 promoter indirectly.
In accordance with the in vitro evidence for the inhibition of IL-6 gene expression by androgens and the role of this cytokine in osteoclast development (38) (39) (40) , the results of the in vivo studies presented in this paper demonstrate that loss of androgens causes an IL-6-mediated increase in osteoclast formation and bone loss. In fact, the evidence that 11L-6 knockout mice are protected from the loss of trabecular bone caused by orchidectomy argues in favor of the contention that IL-6-mediated upregulation of osteoclastogenesis in the bone marrow is the essential triggering event of this bone loss. The findings from the orchidectomized 11L-6 deficient mice are practically identical to those of Poli et al. demonstrating that 11L-6 knockout mice fail to upregulate CFU-GM and osteoclasts, and are protected from the loss of bone that follows ovariectomy (7) . Hence, similar molecular and cellular mechanisms underlie the pathogenesis of bone loss following the loss of either female or male sex steroids.
Orchidectomy produced a much greater increase in the number of dividing CFU-GM, as compared to the total number of CFU-GM. Consistent with this evidence, administration of either testosterone or the 11L-6 neutralizing antibody produced a greater decrease in the number dividing CFU-GM as compared to the total number of CFU-GM. These observations are in agreement with evidence that IL-6 promotes differentiation of hematopoietic cells by stimulating cell division of early progenitors (41) (42) (43) ; moreover, they strengthen the view that the cascade of events leading to bone loss, following loss of sex steroids, starts in the hematopoietic bone marrow.
An association between reduced levels of dehydroepiandrosterone sulfate and osteoporosis in humans (44) (45) (46) along with evidence that ovariectomy-induced bone loss in the rat is reduced by administration of dehydroepiandrosterone (47) has led to the idea that adrenal androgens may have bone protective properties. Our findings that dehydroepiandrosterone sulfate, androstenediol, and androstenedione suppress the activity of the human IL-6 promoter raise the possibility that the bone protective effects of this class of steroids as well might be due to their ability to suppress the production of IL-6.
Although the above evidence leads to the irrefutable conclusion that 11L-6 is an essential mediator of the bone loss that occurs upon loss of either female or male sex steroids, other observations have led to the suggestion that 1L-1 and TNF also play a role in the upregulation of osteoclastogenesis and the loss of bone that follows loss of ovarian function. Specifically, using a bioassay to quantify IL-1, Pacifici and coworkers have reported that spontaneous IL-1 production by cultured peripheral blood monocytes is elevated in patients with high-turnover osteoporosis (48) . These findings, however, could not be confirmed by the results of studies whereby IL-1 levels were determined by an ELISA as opposed to the bioassay (49, 50 (53) . In direct conflict with the contention that IL-1 production increases after loss of estrogens, Hu et al. (54) and Flynn (55) have found that estrogens stimulate IL-1 production by rat peritoneal macrophages in vitro, and that ovariectomy decreases and estrogen replacement increases IL-1 production by these cells. Notably, Flynn observed that testosterone had no effect on IL-1. In line with these later studies, Keeting et al. reported that 173-estradiol increases the levels of IL-1 mRNA in human osteoblastic cells (56) . On the other hand, H. Fox (personal communication) has found that 173-estradiol has no effect on IL-1 expression in the monocytic P388D1 and J774 cell lines, and in bone marrow-derived macrophages; whereas it does inhibit IL-6 production in all these cells. Taken together with the well recognized limitations of the IL-1 bioassay (57), including vulnerability to inhibitory molecules and the synergistic effects of more than one cytokine on the bioassay target cells, these observations dispute the contention that the IL-1 gene is upregulated following loss of estrogens (or androgens). Hence, the suggestion that IL-1 mediates the bone loss caused by loss of gonadal function lacks the prerequisite mechanistic foundation.
The unsubstantiated evidence for the upregulation of IL-1 after loss of estrogens notwithstanding, Kimble et al. (51) reported that administration of IL-1 receptor antagonist (IL-lra) immediately following ovariectomy had only a small effect compared to 17,6-estradiol in preventing the ovariectomy-induced bone loss in the rat, as measured by densitometry. However, when IL-lra was administered 4 wk after ovariectomy, it was as effective as 17,6-estradiol in preventing subsequent bone loss. On the other hand, Kalu et al. found that IL-lra administration initiated at 10 days following ovariectomy in the rat did not prevent the bone loss manifested at one month following the operation, when bone was analyzed by quantitative histomorphometry (58) . Unlike their findings in the rat, Kitazawa et al. more recently reported that administration of the IL-lra or even a TNF binding protein to ovariectomized mice immediately following the operation decreased osteoclast formation in vitro and the urinary excretion of pyridinoline cross-links (a marker of bone resorption), as did administration of 17,6-estradiol (52) .
Work from our laboratory may help to reconcile some of these apparent discrepancies. Indeed, we have found that blockade of the activity of IL-1, TNF, IL-11, GM-CSF, or TGF,6 in vitro abrogates osteoclast formation in murine marrow cultures irrespective of the estrogen status of the donor animal, suggesting strongly that each of these cytokines is essential for osteoclast development (59, 60) . Therefore, IL-1 and TNF antagonists may well inhibit the bone loss caused by the IL-6-mediated increased osteoclastogenesis, without needing to invoke upregulation of IL-1 or TNF production. In any event, the evidence that IL-6 knockout mice are protected from the IL-6, Bone Homeostasis and Androgens 2893 increased osteoclastogenesis and bone loss that follows the loss of either estrogens or androgens, suggests strongly that upregulation of IL-6 is the triggering event for these phenomena and that the putative increases in IL-1 or TNF after ovariectomy are, at best, consequences of the removal of the inhibitory effects of sex steroids on IL-6.
In summary, our findings and those of others strongly suggest that the cellular and molecular mechanisms which lead to the bone loss caused by androgen deficiency in the male are similar, if not identical, to the mechanisms which underlie the bone loss caused by estrogen deficiency in the female and that IL-6 is an essential pathogenetic factor in both of these conditions. Whether IL-6 is the sole pathogenetic factor will remain uncertain until definitive evidence for or against direct regulation of other cytokines by sex steroids in bone marrow cells is obtained.
